193 related articles for article (PubMed ID: 15083594)
1. Acetyl-CoA carboxylase inhibition for the treatment of metabolic syndrome.
Harwood HJ
Curr Opin Investig Drugs; 2004 Mar; 5(3):283-9. PubMed ID: 15083594
[TBL] [Abstract][Full Text] [Related]
2. Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition.
Harwood HJ
Expert Opin Ther Targets; 2005 Apr; 9(2):267-81. PubMed ID: 15934915
[TBL] [Abstract][Full Text] [Related]
3. Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals.
Harwood HJ; Petras SF; Shelly LD; Zaccaro LM; Perry DA; Makowski MR; Hargrove DM; Martin KA; Tracey WR; Chapman JG; Magee WP; Dalvie DK; Soliman VF; Martin WH; Mularski CJ; Eisenbeis SA
J Biol Chem; 2003 Sep; 278(39):37099-111. PubMed ID: 12842871
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of mammalian acetyl-CoA carboxylase.
Corbett JW; Harwood JH
Recent Pat Cardiovasc Drug Discov; 2007 Nov; 2(3):162-80. PubMed ID: 18221116
[TBL] [Abstract][Full Text] [Related]
5. Expression, purification, and characterization of human and rat acetyl coenzyme A carboxylase (ACC) isozymes.
Cheng D; Chu CH; Chen L; Feder JN; Mintier GA; Wu Y; Cook JW; Harpel MR; Locke GA; An Y; Tamura JK
Protein Expr Purif; 2007 Jan; 51(1):11-21. PubMed ID: 16854592
[TBL] [Abstract][Full Text] [Related]
6. Regulatory enzymes of mitochondrial beta-oxidation as targets for treatment of the metabolic syndrome.
Schreurs M; Kuipers F; van der Leij FR
Obes Rev; 2010 May; 11(5):380-8. PubMed ID: 19694967
[TBL] [Abstract][Full Text] [Related]
7. Hepatic de novo lipogenesis is present in liver-specific ACC1-deficient mice.
Harada N; Oda Z; Hara Y; Fujinami K; Okawa M; Ohbuchi K; Yonemoto M; Ikeda Y; Ohwaki K; Aragane K; Tamai Y; Kusunoki J
Mol Cell Biol; 2007 Mar; 27(5):1881-8. PubMed ID: 17210641
[TBL] [Abstract][Full Text] [Related]
8. LKB1 and the regulation of malonyl-CoA and fatty acid oxidation in muscle.
Thomson DM; Brown JD; Fillmore N; Condon BM; Kim HJ; Barrow JR; Winder WW
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1572-9. PubMed ID: 17925454
[TBL] [Abstract][Full Text] [Related]
9. A herbal extract with acetyl-coenzyme A carboxylase inhibitory activity and its potential for treating metabolic syndrome.
Chen CH; Chang MY; Lin YS; Lin DG; Chen SW; Chao PM
Metabolism; 2009 Sep; 58(9):1297-305. PubMed ID: 19500808
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-activity relationships of N-{3-[2-(4-alkoxyphenoxy)thiazol-5-yl]-1- methylprop-2-ynyl}carboxy derivatives as selective acetyl-CoA carboxylase 2 inhibitors.
Gu YG; Weitzberg M; Clark RF; Xu X; Li Q; Zhang T; Hansen TM; Liu G; Xin Z; Wang X; Wang R; McNally T; Zinker BA; Frevert EU; Camp HS; Beutel BA; Sham HL
J Med Chem; 2006 Jun; 49(13):3770-3. PubMed ID: 16789734
[TBL] [Abstract][Full Text] [Related]
11. Role of malonyl-CoA in heart disease and the hypothalamic control of obesity.
Folmes CD; Lopaschuk GD
Cardiovasc Res; 2007 Jan; 73(2):278-87. PubMed ID: 17126822
[TBL] [Abstract][Full Text] [Related]
12. Acetyl-CoA carboxylases 1 and 2 show distinct expression patterns in rats and humans and alterations in obesity and diabetes.
Kreuz S; Schoelch C; Thomas L; Rist W; Rippmann JF; Neubauer H
Diabetes Metab Res Rev; 2009 Sep; 25(6):577-86. PubMed ID: 19618481
[TBL] [Abstract][Full Text] [Related]
13. Design of small molecule inhibitors of acetyl-CoA carboxylase 1 and 2 showing reduction of hepatic malonyl-CoA levels in vivo in obese Zucker rats.
Bengtsson C; Blaho S; Saitton DB; Brickmann K; Broddefalk J; Davidsson O; Drmota T; Folmer R; Hallberg K; Hallén S; Hovland R; Isin E; Johannesson P; Kull B; Larsson LO; Löfgren L; Nilsson KE; Noeske T; Oakes N; Plowright AT; Schnecke V; Ståhlberg P; Sörme P; Wan H; Wellner E; Oster L
Bioorg Med Chem; 2011 May; 19(10):3039-53. PubMed ID: 21515056
[TBL] [Abstract][Full Text] [Related]
14. Review of recent acetyl-CoA carboxylase inhibitor patents: mid-2007-2008.
Corbett JW
Expert Opin Ther Pat; 2009 Jul; 19(7):943-56. PubMed ID: 19552511
[TBL] [Abstract][Full Text] [Related]
15. Discovery of acetyl-coenzyme A carboxylase 2 inhibitors: comparison of a fluorescence intensity-based phosphate assay and a fluorescence polarization-based ADP Assay for high-throughput screening.
Liu Y; Zalameda L; Kim KW; Wang M; McCarter JD
Assay Drug Dev Technol; 2007 Apr; 5(2):225-35. PubMed ID: 17477831
[TBL] [Abstract][Full Text] [Related]
16. Brain acetyl-CoA carboxylase: isozymic identification and studies of its regulation during development and altered nutrition.
Spencer EB; Bianchi A; Widmer J; Witters LA
Biochem Biophys Res Commun; 1993 Apr; 192(2):820-5. PubMed ID: 8097913
[TBL] [Abstract][Full Text] [Related]
17. Gene expression analysis in rats treated with experimental acetyl-coenzyme A carboxylase inhibitors suggests interactions with the peroxisome proliferator-activated receptor alpha pathway.
Waring JF; Yang Y; Healan-Greenberg CH; Adler AL; Dickinson R; McNally T; Wang X; Weitzberg M; Xu X; Lisowski A; Warder SE; Gu YG; Zinker BA; Blomme EA; Camp HS
J Pharmacol Exp Ther; 2008 Feb; 324(2):507-16. PubMed ID: 18025247
[TBL] [Abstract][Full Text] [Related]
18. Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats.
Harriman G; Greenwood J; Bhat S; Huang X; Wang R; Paul D; Tong L; Saha AK; Westlin WF; Kapeller R; Harwood HJ
Proc Natl Acad Sci U S A; 2016 Mar; 113(13):E1796-805. PubMed ID: 26976583
[TBL] [Abstract][Full Text] [Related]
19. (4-Piperidinyl)-piperazine: a new platform for acetyl-CoA carboxylase inhibitors.
Chonan T; Oi T; Yamamoto D; Yashiro M; Wakasugi D; Tanaka H; Ohoka-Sugita A; Io F; Koretsune H; Hiratate A
Bioorg Med Chem Lett; 2009 Dec; 19(23):6645-8. PubMed ID: 19853443
[TBL] [Abstract][Full Text] [Related]
20. AMP-activated protein kinase and coordination of hepatic fatty acid metabolism of starved/carbohydrate-refed rats.
Assifi MM; Suchankova G; Constant S; Prentki M; Saha AK; Ruderman NB
Am J Physiol Endocrinol Metab; 2005 Nov; 289(5):E794-800. PubMed ID: 15956049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
